期刊
MICROORGANISMS
卷 9, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/microorganisms9040806
关键词
convalescent plasma; COVID-19; efficacy; SARS-CoV-2 antibodies
类别
资金
- Intramural Research Program of the National Cancer Institute
- National Cancer Institute, National Institutes of Health
- SYNENOSIS
A multicenter phase II study evaluated the efficacy and safety of convalescent plasma (CP) in severe COVID-19 patients, finding that CP recipients had significantly reduced risk of death, improved overall survival, and higher chances of extubation. Higher levels of antibodies in the CP were associated with reduced risk of death, and CP infusion was safe with minimal adverse events. Early use of CP may be a safe and effective treatment for severe COVID-19 patients.
COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of 7 days from symptom onset. During a median follow-up of 28.5 days, 56/60 patients fully recovered and 1 patient remained in the ICU. The death rate in the CP group was 3.4% vs. 13.6% in the control group. By multivariate analysis, CP recipients demonstrated a significantly reduced risk of death [HR: 0.04 (95% CI: 0.004-0.36), p: 0.005], significantly better overall survival by Kaplan-Meir analysis (p < 0.001), and increased probability of extubation [OR: 30.3 (95% CI: 2.64-348.9), p: 0.006]. Higher levels of antibodies in the CP were independently associated with significantly reduced risk of death. CP infusion was safe with only one grade 3 adverse event (AE), which easily resolved. CP used early may be a safe and effective treatment for patients with severe COVID-19 (trial number NCT04408209).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据